Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT
Autologous Mesenchymal Stromal Cells and Islet Co-transplantation to Enhance Islet Survival and Function in Chronic Pancreatitis Patients Undergo Total Pancreatectomy and Islet Autotransplantation
Medical University of South Carolina
42 participants
Dec 1, 2021
INTERVENTIONAL
Conditions
Summary
This is a clinical trial for chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for one-year post-transplant.
Eligibility
Inclusion Criteria3
- Diagnosis of CP and scheduled for TP-IAT;
- ≥18 years old;
- Diabetes with HbA1c <12%.
Exclusion Criteria3
- Patients who are under immunosuppression;
- Pregnant and breastfeeding women.
- Patients who have liver damage based on ALT, AST, and total bilirubin levels (>3 times normal levels);
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MSC transplantation
Standard of Care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05095532